Researchers from the University of California, San Diego, presented a new study at the 2014 American Thoracic Society International Conference revealing the effects of pulmonary thromboendarterectomy (PTE) in patients with chronic pulmonary thromboembolic disease, suggesting a positive effect in patients’ conditions after the procedure. Daniel Crouch, MD, pulmonary and critical fellow…
Search results for:
The lung functioning of pulmonary hypertension patients treated with Bayer’s Adempas improved by 50 percent over a median of six years and stabilized in another 45 percent, according to a Phase 2 clinical trial. Those findings and others indicate that Adempas is a good long-term therapy for pulmonary…
This podcast series, created and produced by phaware, is being offered as a regular guest feature on Pulmonary Hypertension News to bring the voices and life experiences of PH patients, family members, caregivers, healthcare specialists, and others to our readers. You may listen to the podcast directly, or read it…
This podcast series, created and produced by phaware, is being offered as a regular guest feature on Pulmonary Hypertension News to bring the voices and life experiences of PH patients, family members, caregivers, healthcare specialists, and others to our readers. You may listen to the podcast directly, or read it…
Adempas (riociguat) is an oral therapy approved to improve exercise capacity and World Health Organization functional class in adults with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension, and to delay clinical worsening in PAH. It's available as oral tablets to be taken three times daily.
Treatment with Tracleer (bosentan) is effective in patients with pulmonary arterial hypertension (PAH), a new review study and analysis of data from clinical trials shows. The research, “Bosentan Therapy for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Systemic Review and…
This podcast series, created and produced by phaware, is being offered as a regular guest feature on Pulmonary Hypertension News to bring the voices and life experiences of PH patients, family members, caregivers, healthcare specialists, and others to our readers. You may listen to the podcast directly, or read…
[vc_row][vc_column][vc_column_text]Pulmonary hypertension (PH) is a rare but life-threatening lung disease that occurs when the pulmonary arteries become narrowed and stiff. The pulmonary arteries are the vessels that move blood from the heart to the lungs, and when they are obstructed, the heart needs to work harder to pump the blood. The…
Having fewer very fine blood vessels in the fold of skin at the base of the fingernails appears to be linked to an increased risk of clinical worsening in pulmonary arterial hypertension (PAH), a study in the Netherlands suggests. People with chronic thromboembolic pulmonary hypertension (CTEPH) also had…
News
Pulmonary Hypertension Study Finds Increased Levels of Protein, CXCL13, in Patient Tissues and Blood
German researchers evaluating a possible new biomarker for pulmonary arterial hypertension (PAH) found that the molecule, known as chemokine CXC ligand 13 (CXCL13), was higher in the blood serum and lung tissue of people with PAH — suggesting a pathogenic role but one short of serving as a disease marker. The report,…
Pulmonary hypertension is a chronic and progressive disease characterized by high blood pressure in the pulmonary arteries, the blood vessels of the lungs. There are many potential causes of the disease that, along with how early the disease is diagnosed and when treatment…